-
Jiangxi Healthcare Security Administration Launches New VBP Tender
•
The Jiangxi Healthcare Security Administration (JHSA) has released a notice of a new volume-based procurement (VBP) tender. Jiangxi’s JHSA will lead a 16-region alliance covering Inner Mongolia, Jilin, Heilongjiang, Zhejiang, Henan, Hunan, Guangxi, Hainan, Chongqing, Guizhou, Shaanxi, Qinghai, Ningxia, Xinjiang, and the Xinjiang Production and Construction Corps. This initiative aims…
-
Fapon Biotech Partners with CR Pharma to Develop IVD Open Platform Ecosystem
•
China-based biotech Fapon Biotech Inc. has announced a partnership with China Resources Pharmaceutical Commercial Group Medical Device Co., Ltd to develop an in vitro diagnostics (IVD) open platform ecosystem. The collaboration aims to enhance the development and market presence of IVD solutions. Financial details of the partnership were not disclosed.…
-
Henlius’ Serplulimab Phase III Study Approved in Spain for LS-SCLC
•
China-based Shanghai Henlius Biotech (HKG: 2696) has announced that its global, multi-center Phase III clinical study (NCT05353257) for HaiSiZhuang (serplulimab) in limited stage small-cell lung cancer (LS-SCLC) has been approved in Spain, a member country of the European Union (EU). The study will assess the PD-1 inhibitor combined with chemotherapy…
-
Hainan Poly Pharm Wins Finland Approval for Generic Cytovene-IV
•
China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) has announced receiving marketing approval from the Finland National Agency for Medicines for its generic version of Roche’s Cytovene-IV (ganciclovir). The approval marks a significant expansion of the company’s market presence in Europe. The targeted indications include the treatment of cytomegalovirus retinitis…
-
Kangtai Biological Completes Phase III Clinical Data Analysis for COVID-19 Vaccine
•
China-based Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has announced the completion of the analysis of key Phase III clinical data for its in-house developed COVID-19 inactivated vaccine (Vero cells). The study assessed the vaccine’s efficacy and safety in a global, multi-center, randomized, double-blind, placebo-controlled trial. Study DetailsThe Phase…
-
Jiangxi Leads 22-Province Alliance in VBP for Liver Function Test Reagents
•
The provincial drug and medical consumables centralized procurement joint meeting office of Jiangxi has released a notification indicating that the province will lead the 22-province alliance volume-based procurement (VBP) of liver function biochemical test reagents. The procurement cycle is set for two years, with a possible one-year extension. The event…
-
Fapon Biotech Partners with Roche Diagnostics at China International Import Expo
•
China-based biotech Fapon Biotech Inc. has announced a partnership with Swiss major Roche Diagnostics at the 5th China International Import Expo (CIIE). The collaboration aims to deepen cooperation in the field of raw material product technical services and molecular diagnostics. The two companies plan to fully integrate their respective resources…
-
China’s Jiangsu Bioda Gains NMPA Approval for Innovative Artificial Blood Vessel
•
The National Medical Products Administration (NMPA) has granted marketing approval to China-based Jiangsu Bioda Life Science Co Ltd’s innovative artificial blood vessel. This marks a significant milestone in the development and commercialization of advanced medical devices in China. Product ProfileThe artificial blood vessel is primarily composed of PET thread and…
